SCG Cell Therapy
Singapore, Singapore· Est.
A Singapore biotech engineering pathogen‑specific TCR‑T cell therapies for infection‑linked cancers.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A Singapore biotech engineering pathogen‑specific TCR‑T cell therapies for infection‑linked cancers.
OncologyInfectious Diseases
Technology Platform
Proprietary TCR screening platform that isolates high‑affinity natural TCRs against pathogen‑derived pMHC ligands, enabling autologous TCR‑T cell therapies for infection‑associated cancers.
Opportunities
Expanding the TCR‑T platform to other oncogenic pathogens and leveraging the Singapore manufacturing hub could unlock a broad pipeline of infection‑driven cancer therapies.
Risk Factors
Clinical efficacy and safety remain unproven; manufacturing autologous cell products is complex and costly, and regulatory pathways for pathogen‑specific TCR therapies are still evolving.
Competitive Landscape
SCG differentiates from broader TCR‑T developers by targeting viral antigens such as HBsAg, offering a clear mechanistic advantage in pathogen‑associated cancers.